Tenaya Therapeutics (TNYA) Cash & Equivalents (2020 - 2026)

Tenaya Therapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $80.9 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 50.45% year-over-year to $80.9 million in Q1 2026; TTM through Mar 2026 was $80.9 million, a 50.45% increase from a year earlier, with the FY2025 full-year figure at $100.5 million, up 2225.86% from the prior year.
• Cash & Equivalents eased to $80.9 million in Q1 2026 per TNYA's latest filing, from $100.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $100.5 million in Q4 2025 and bottomed at $4.3 million in Q4 2024.
• The 5-year median for Cash & Equivalents is $58.1 million (2024), against an average of $56.2 million.
• Across the five-year window, Cash & Equivalents slumped 90.54% in 2024 and soared 2225.86% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $95.3 million in 2022, then sank by 52.05% to $45.7 million in 2023, then slumped by 90.54% to $4.3 million in 2024, then surged by 2225.86% to $100.5 million in 2025, then declined by 19.54% to $80.9 million in 2026.
• Per Business Quant, the three latest TNYA Cash & Equivalents figures stand at $80.9 million (Q1 2026), $100.5 million (Q4 2025), and $56.3 million (Q3 2025).